Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary objective of this study is to allow access and evaluate the safety of crizotinib for patients in Japan with advanced NSCLC harboring a translocation or inversion involving the ROS1 oncogene.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

NCT03672643

ALK or ROS1-positive NSCLC

TERMINATED PHASE4

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

NCT01945021

Non Small Cell Lung Cancer ROS1 Proto Oncogene Crizotinib

COMPLETED PHASE2

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03410108

ALK-positive Advanced NSCLC

COMPLETED PHASE2

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

NCT03646994

Non-small Cell Lung Cancer

RECRUITING

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

NCT01500824

Non-Small Cell Lung Cancer

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms Carcinoma, Non-Small-Cell Lung

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

crizotinib

Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic.
* Positive for translocation or inversion events involving the ROS1 gene as determined by protocol defined test.
* ECOG performance status 0 to 2.
* Adequate organ function
* Patients with brain metastases are eligible if neurologically stable for at least 2 weeks and have no ongoing requirement for corticosteroids.
* Male patients able to father children and female patients of childbearing potential and at risk for pregnancy must agree to use 2 highly effective methods of contraception throughout the study and for at least 90 days after the last dose of crizotinib.

Exclusion Criteria

* Currently receiving crizotinib or any investigational products.
* Prior therapy specifically directed against ROS1 fusion genes including crizotinib.
* Carcinomatous meningitis or leptomeningeal disease.
* Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function.
* Ongoing uncontrolled congestive heart failure (CHF) and any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident including transient ischemic attack.
* Ongoing cardiac dysrhythmias of CTCAE Grade 2, uncontrolled atrial fibrillation of any grade, or QTc more than 480 msec.
* History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis.
* Pregnant female patients; breastfeeding female patients.
* Use of drugs or foods including known potent CYP3A4 inhibitors, known potent CYP3A4 inducers and CYP3A4 substrates with narrow therapeutic indices

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No